While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune ...

On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase III ...

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

Venus Williams is back on the professional tennis tour at age 45 and will be returning to the U.S. Open next week for her ...

Good news in research for Novartis. The pharmaceutical giant has achieved the hoped-for results for Ianalumab, a candidate ...

Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active Sjögren's disease. Both trials met the primary endpoint of ...

Adults with Sjögren’s disease complicated by a subtype of cutaneous vasculitis are more likely to develop non-Hodgkin’s ...

Ianalumab is a fully human monoclonal antibody designed to deplete B cells via antibody-dependent cellular toxicity and inhibit BAFF-R-mediated signals of B cell function and survival.

Among these, 300 patients were treated with VELDONA®, while the remainder received placebo. The trials demonstrated that VELDONA® significantly improved dryness-related symptoms--such as dry mouth and ...

The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a ...